<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906514</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL15_0235</org_study_id>
    <nct_id>NCT02906514</nct_id>
  </id_info>
  <brief_title>Priming of Cardiopulmonary Bypass With Hydroxyethyl Starch 130/0.4 or Sodium Chloride 0.9% : Pilot Study in Adult Elective Conventional Cardiac Surgery</brief_title>
  <acronym>OPTIMUS-PRIME</acronym>
  <official_title>Priming of Cardiopulmonary Bypass With Hydroxyethyl Starch 130/0.4 or Sodium Chloride 0.9% : a Double Blind Randomized Pilot Study in Adult Elective Conventional Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Best priming for cardiopulmonary bypass in cardiac surgery is unknown. Efficacy and toxicity
      of Hydroxyethyl Starch 130/0.4 used in this context are uncertain.

      The aim of this pilot study is to determine if Hydroxyethyl Starch 130/0.4 is more effective
      than Sodium Chloride 0.9% in short term hemodynamic purpose without side renal or hemostatic
      effect.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Supplementary volume of fluid administered during cardiopulmonary bypass (ml)</measure>
    <time_frame>Day 1 (From initiation to separation of cardiopulmonary bypass)</time_frame>
    <description>Fluid administered during cardiopulmonary bypass for normal functioning, with the exception of blood product, cardioplegia and priming</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of preoperative hematocrit and lowest hematocrit during cardiopulmonary bypass</measure>
    <time_frame>Day 1 (From initiation to separation of cardiopulmonary bypass)</time_frame>
    <description>Continuous monitoring of hematocrit during cardiopulmonary bypass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid balance</measure>
    <time_frame>Hour 0</time_frame>
    <description>Difference between total intraoperative volume of fluids administered (vascular filling, blood products, cardioplegia, priming) and total intraoperative volume of fluids loss (urine, bleedings)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid balance</measure>
    <time_frame>Hour 12</time_frame>
    <description>Difference between total intraoperative volume of fluids administered (vascular filling, blood products, cardioplegia, priming) and total intraoperative volume of fluids loss (urine, bleedings)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment score</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment score</measure>
    <time_frame>Hour 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid-Base parameters : arterial pH</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid-Base parameters : Base Excess</measure>
    <time_frame>Hour 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid-Base parameters : Base Excess</measure>
    <time_frame>H24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid-Base parameters : Lactatemia</measure>
    <time_frame>Hour 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid-Base parameters : Lactatemia</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid-Base parameters : Chloremia</measure>
    <time_frame>Hour 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid-Base parameters : Chloremia</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters : platelets</measure>
    <time_frame>Hour 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters : prothrombin</measure>
    <time_frame>Hour 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters : activated partial thromboplastin</measure>
    <time_frame>Hour 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters : fibrinogen level</measure>
    <time_frame>Hour 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters : platelets</measure>
    <time_frame>H24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters : prothrombin</measure>
    <time_frame>H24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters : activated partial thromboplastin</measure>
    <time_frame>H24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters : fibrinogen level</measure>
    <time_frame>H24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Hour 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical bleeding</measure>
    <time_frame>Hour 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical bleeding</measure>
    <time_frame>during surgical drainage, an average of 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revision surgery for bleeding</measure>
    <time_frame>Hour 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay for ablation of surgical drainage</measure>
    <time_frame>Day of ablation of surgical drainage, 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiemetic medication use</measure>
    <time_frame>end of intensive care unit stay, 24 hours</time_frame>
    <description>Any antiemetic medication used during this period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay to first extubation (number of hours)</measure>
    <time_frame>Hour of first extubation, an average of 5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit stay (number oh days)</measure>
    <time_frame>Day of intensive care unit stay exit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay (number of days)</measure>
    <time_frame>Day of hospital exit, an average of 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine level variation</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine level variation</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine level variation</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy use during intensive care stay</measure>
    <time_frame>end of intensive care unit stay, an average of 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy dependency</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy dependency</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of any cause</measure>
    <time_frame>During hospital stay, an average of 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of any cause</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of any cause</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Extracorporeal Circulation</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Hydroxyethyl starch 130/0.4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Chloride 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non balanced Hydroxyethyl starch 130/0.4 (VoluvenÂ®, Fresenius)</intervention_name>
    <description>1000mL used for cardiopulmonary bypass priming</description>
    <arm_group_label>Hydroxyethyl starch 130/0.4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 0.9% (Fresenius)</intervention_name>
    <description>1000mL used for cardiopulmonary bypass priming</description>
    <arm_group_label>Sodium Chloride 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective conventional cardiac surgery with cardiopulmonary
             bypass

          -  Patients insured under the French social security system

        Exclusion Criteria:

          -  Pregnancy

          -  Patients placed under guardianship

          -  Urgent surgery

          -  Cardiac surgery without cardiopulmonary bypass

          -  Anterior cardiac surgery

          -  Non conventional cardiac surgery (mini-invasive surgery, dual valve replacement, right
             heart surgery)

          -  Simultaneous inclusion in another study with potential interference in outcomes

          -  Heparin-induced thrombocytopenia

          -  Chronic renal insufficiency (glomerular filtration rate &lt; 60mL.min-1.m-2)

          -  Nature/nurture hemostasis disorders, in particular Von Willebrand disease and
             hemophilia

          -  Hydroxyethyl Starch allergy

          -  Weight under 33 kg

          -  Mechanical hemodynamic support at the end of the surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hopital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydroxyethyl Starch</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>Priming of cardiopulmonary bypass</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

